List view / Grid view

hepatocellular carcinoma (HCC)

Roche cancer immunotherapy receives new EU approval

16 January 2024 | By

The subcutaneous injection of the novel cancer immunotherapy Tecentriq® (atezolizumab) could provide a quicker alternative to intravenous infusion, research shows.

news

Roche subcutaneous cancer immunotherapy granted MHRA approval

29 August 2023 | By Catherine Eckford (European Pharmaceutical Review)

The first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain on the NHS reduces treatment time to under ten minutes.

news

Imfinzi plus Imjudo approved in EU for advanced cancers

23 February 2023 | By Catherine Eckford (European Pharmaceutical Review)

Hepatocellular carcinoma and non-small cell lung cancer patients are set to benefit from the recent approval of Imfinzi plus Imjudo combinations in the EU.

news

Clinical trial-first for liver cancer immunotherapy combo

19 January 2023 | By Catherine Eckford (European Pharmaceutical Review)

IMbrave050 is the first Phase III study to show a cancer immunotherapy combo reduced risk of disease recurrence for early-stage hepatocellular carcinoma.

news

CHMP meeting highlights – December 2022

19 December 2022 | By Catherine Eckford (European Pharmaceutical Review)

A total of five drugs were recommended for approval at the CHMP’s December meeting, including a gene therapy and two cancer drugs.

drug products of various forms in various types of packaging, including liquid in glass vials and pills/capsules in blister packages - idea of medicines or pharmaceuticals

news

EMA human medicines committee (CHMP) highlights, September 2022

21 September 2022 | By Hannah Balfour (European Pharmaceutical Review)

In its latest meeting, the Committee for Medicinal Products for Human Use (CHMP) recommended 12 medicines for approval, including those for rare diseases, osteoporosis and cancer.

news

Phase III trial shows tislelizumab improves outcomes for liver cancer patients

16 August 2022 | By Caroline Peachey (European Pharmaceutical Review)

Phase III trial results indicate BeiGene’s tislelizumab improved overall survival in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib.

news

Study finds Keytruda^® improves overall survival in HCC patients

20 January 2022 | By European Pharmaceutical Review

The data adds to the body of evidence relating to the use of Keytruda® as a monotherapy in second-line HCC post sorafenib.

light micrograph of hepatocellular carcinoma

news

Imfinzi™ plus tremelimumab: “unprecedented survival” in unresectable liver cancer

19 January 2022 | By Hannah Balfour (European Pharmaceutical Review)

Almost a third of unresectable hepatocellular carcinoma patients were alive at three years on tremelimumab and Imfinzi regimen.

Hepatocellular carcinoma under microscope

news

Imfinzi^™ improves liver cancer survival in Phase III trial

15 October 2021 | By Anna Begley (European Pharmaceutical Review)

Imfinzi (durvalumab) demonstrated a meaningful overall survival (OS) benefit versus sorafenib as a first-line treatment for liver cancer.

Doctor, nurse or scientist hand in blue nitrile gloves drawing a clear liquid into a syringe from a vial - idea of a vaccine or injection

news

Novel ionic liquid enables uniform chemotherapy delivery in solid tumours

15 February 2021 | By Hannah Balfour (European Pharmaceutical Review)

Co-injecting doxorubicin with LATTE, a novel ionic liquid formulation, resulted in uniform chemotherapy delivery and successful ablation in solid tumours.

news

Phenformin-mTOR inhibitor combination shows promise in HCC

28 June 2018 | By European Pharmaceutical Review

A combination of mTOR inhibitors and Phenformin leads to an increase in overall survival...

news

FDA grants two orphan drug designations for HCC

18 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

The FDA has granted two orphan drug designations for T cell therapy products for the treatment of hepatocellular carcinoma...

news

Nexavar receives final appraisal for primary liver cancer

10 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...

news

Bayer receives EU approval for Regorafenib

8 August 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

Bayer have announced the European Commission has granted marketing authorisation for Stivarga...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

hepatocellular carcinoma (HCC)